← Back to Screener
Immucell Corp (ICCC)
Price$7.54
Favorite Metrics
Price vs S&P 500 (26W)11.34%
Price vs S&P 500 (4W)20.01%
Market Capitalization$69.30M
All Metrics
P/CF (Annual)193.63x
Book Value / Share (Quarterly)$3.29
P/TBV (Annual)1.67x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.18%
Cash Flow / Share (Quarterly)$0.08
Price vs S&P 500 (YTD)20.93%
Gross Margin (TTM)41.40%
Net Profit Margin (TTM)-3.76%
EPS (TTM)$-0.11
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-0.11
Revenue Growth (5Y)12.50%
EPS (Annual)$-0.12
ROI (Annual)-5.67%
Gross Margin (Annual)41.40%
Net Profit Margin (5Y Avg)-11.76%
Cash / Share (Quarterly)$0.43
P/E Basic Excl Extra (TTM)25.81x
Revenue Growth QoQ (YoY)-1.61%
ROA (Last FY)-4.78%
Revenue Growth TTM (YoY)4.35%
EBITD / Share (TTM)$0.14
ROE (5Y Avg)-8.60%
Operating Margin (TTM)7.51%
Cash Flow / Share (Annual)$-0.01
P/B Ratio2.33x
P/B Ratio (Quarterly)1.90x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.70x
Net Interest Coverage (TTM)-3.37x
ROA (TTM)5.07%
EV / EBITDA (TTM)13.93x
EPS Incl Extra (Annual)$-0.12
Current Ratio (Annual)3.41x
Quick Ratio (Quarterly)1.62x
3-Month Avg Trading Volume0.02M
52-Week Price Return38.18%
P/E Incl Extra (TTM)25.81x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.29
P/S Ratio (Annual)2.51x
Asset Turnover (Annual)0.59x
52-Week High$7.82
Operating Margin (5Y Avg)-8.41%
EPS Excl Extra (Annual)$-0.12
CapEx CAGR (5Y)-19.64%
Tangible BV CAGR (5Y)-0.98%
26-Week Price Return15.33%
Quick Ratio (Annual)1.72x
13-Week Price Return13.94%
Total Debt / Equity (Annual)0.38x
Current Ratio (Quarterly)4.21x
Enterprise Value$74.903
Revenue / Share Growth (5Y)7.56%
Asset Turnover (TTM)0.61x
Book Value / Share Growth (5Y)-5.29%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.49x
Pretax Margin (Annual)-3.72%
Cash / Share (Annual)$0.42
3-Month Return Std Dev50.83%
Gross Margin (5Y Avg)35.95%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-4.73%
EBITDA Interim CAGR (5Y)12.55%
ROE (Last FY)-7.84%
Net Interest Coverage (Annual)7.49x
EPS Basic Excl Extra (Annual)$-0.12
P/FCF (TTM)25.75x
Receivables Turnover (TTM)11.42x
EV / Free Cash Flow (TTM)104.71x
Total Debt / Equity (Quarterly)0.32x
EPS Incl Extra (TTM)$-0.11
Receivables Turnover (Annual)8.90x
ROI (TTM)5.95%
P/S Ratio (TTM)2.51x
Pretax Margin (5Y Avg)-11.72%
Revenue / Share (Annual)$3.06
Tangible BV / Share (Annual)$3.06
Price vs S&P 500 (52W)8.35%
P/E Ratio (TTM)25.81x
Year-to-Date Return23.58%
5-Day Price Return5.70%
EPS Normalized (Annual)$-0.12
ROA (5Y Avg)-5.24%
Net Profit Margin (Annual)-3.76%
Month-to-Date Return20.06%
Cash Flow / Share (TTM)$-0.47
EBITD / Share (Annual)$-0.11
Operating Margin (Annual)5.97%
LT Debt / Equity (Annual)0.33x
P/CF (TTM)34.83x
ROI (5Y Avg)-6.06%
P/E Excl Extra (TTM)25.81x
LT Debt / Equity (Quarterly)0.27x
EPS Basic Excl Extra (TTM)$-0.11
P/TBV (Quarterly)1.90x
P/B Ratio (Annual)1.67x
Inventory Turnover (TTM)1.90x
Pretax Margin (TTM)-3.72%
Book Value / Share (Annual)$3.06
Price vs S&P 500 (13W)13.26%
Beta0.33x
P/FCF (Annual)384.99x
Revenue / Share (TTM)$3.06
ROE (TTM)8.00%
52-Week Low$4.52
Analyst Recommendations
Sep 2021
Oct 2021
Nov 2021
Dec 2021
4.14
4.14
4.14
4.14
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ICCCImmucell Corp | 2.51x | 4.35% | 41.40% | — | $7.54 |
IDXXIdexx Laboratories Inc | 10.59x | 10.42% | 61.80% | 14.28% | $569.95 |
LNTHLantheus Holdings, Inc | 3.53x | 0.50% | 61.10% | 40.71% | $83.92 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 299.06x | -5.72% | 89.00% | — | $27.80 |
CLDXCelldex Therapeutics, Inc | 1718.98x | -77.98% | 17.65% | — | $33.86 |
NEOGNeogen Corp | 2.32x | -3.91% | 45.20% | — | $9.24 |
NTLAIntellia Therapeutics, Inc | 26.08x | 16.92% | — | — | $14.16 |
QDELQuidelOrtho Corporation Common Stock | 0.31x | -1.89% | 46.67% | — | $12.69 |
MYGNMyriad Genetics Inc | 0.58x | -1.56% | 69.93% | — | $5.00 |
ACHVAchieve Life Sciences, Inc. | 14.37x | -89.25% | — | — | $4.81 |
TKNOAlpha Teknova, Inc. Common Stock | 3.62x | 7.35% | 33.17% | — | $2.68 |
About
ImmuCell Corp develops and commercializes health products for the dairy and beef cattle industries. The company operates two business segments: Scours (First Defense, a USDA-regulated product to prevent disease in newborn calves) and Mastitis (Re-Tain, an FDA-regulated treatment for subclinical mastitis in dairy cows). The Scours segment generates the majority of company revenue.